Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

  • Glen J. Weiss | gweiss@tgen.org Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Raoul Tibes Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Lisa Blaydorn Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Gayle Jameson Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Molly Downhour Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Erica White Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Ivor Caro Genentech, South San Francisco, CA, United States.
  • Daniel D. Von Hoff Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.

Abstract

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-01
Info
Issue
Section
Case Reports
Keywords:
Basal cell carcinoma, vismodegib, basal cell nevus syndrome, hedgehog
Statistics
  • Abstract views: 1287

  • PDF: 500
  • HTML: 66
How to Cite
Weiss, G. J., Tibes, R., Blaydorn, L., Jameson, G., Downhour, M., White, E., Caro, I., & Von Hoff, D. D. (2011). Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. Dermatology Reports, 3(3), e55. https://doi.org/10.4081/dr.2011.e55

Most read articles by the same author(s)